An Entity of Type: PhysicalEntity100001930, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Not to be confused with Factor Inhibiting HIF Asparaginyl Hydroxylase Inhibitors Hypoxia-inducible factor prolyl hydroxylase Inhibitors (HIF-PHIs) also known as hypoxia-inducible factor stabilizers (HIF stabilizers) are members of a mostly experimental class of drugs that act by inhibiting hypoxia-inducible factor-proline dioxygenase (HIF prolyl-hydroxylase) which is responsible to break down the hypoxia-inducible factor (HIF) under conditions of normal oxygen concentrations.

Property Value
dbo:abstract
  • Not to be confused with Factor Inhibiting HIF Asparaginyl Hydroxylase Inhibitors Hypoxia-inducible factor prolyl hydroxylase Inhibitors (HIF-PHIs) also known as hypoxia-inducible factor stabilizers (HIF stabilizers) are members of a mostly experimental class of drugs that act by inhibiting hypoxia-inducible factor-proline dioxygenase (HIF prolyl-hydroxylase) which is responsible to break down the hypoxia-inducible factor (HIF) under conditions of normal oxygen concentrations. As of 2008 they had been investigated in in cell models for the treatment of anemia, chronic kidney disease (CKD), ischemia including ischemia of the heart tissue, cancer, and others.Research conducted in mice suggests that they may increase hippocampal memory by increasing erythropoietin expression. As of 2021 research focuses mainly on anemia associated with CKD, and to some extent on ischemia. One drug of this class (roxadustat) is marketed in China and Japan for the treatment of anaemia in CKD patients. (en)
  • HIF-PH阻害剤(HIF-PHそがいざい、低酸素誘導因子プロリン水酸化酵素阻害剤、hypoxia-inducible factor prolyl-hydroxylase inhibitor)は、低酸素誘導因子安定化剤(HIF安定化剤)としても知られ、低酸素誘導因子(HIF)の分解に関与するという酵素を阻害することによって作用する、新しい種類の薬剤である。 2008年現在、貧血や慢性腎臓病、がん 、心筋組織への影響などが研究されている。 マウスで行われた研究では、エリスロポエチンの発現を増加させることにより、海馬の記憶を増加させる可能性があることを示唆している。 (ja)
dbo:thumbnail
dbo:wikiPageID
  • 22859273 (xsd:integer)
dbo:wikiPageLength
  • 5544 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1068588248 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • B03X (en)
dbp:biologicalTarget
dbp:caption
  • Roxadustat, the first marketed HIF prolyl-hydroxylase inhibitor (en)
dbp:mechanismOfAction
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • HIF-PH阻害剤(HIF-PHそがいざい、低酸素誘導因子プロリン水酸化酵素阻害剤、hypoxia-inducible factor prolyl-hydroxylase inhibitor)は、低酸素誘導因子安定化剤(HIF安定化剤)としても知られ、低酸素誘導因子(HIF)の分解に関与するという酵素を阻害することによって作用する、新しい種類の薬剤である。 2008年現在、貧血や慢性腎臓病、がん 、心筋組織への影響などが研究されている。 マウスで行われた研究では、エリスロポエチンの発現を増加させることにより、海馬の記憶を増加させる可能性があることを示唆している。 (ja)
  • Not to be confused with Factor Inhibiting HIF Asparaginyl Hydroxylase Inhibitors Hypoxia-inducible factor prolyl hydroxylase Inhibitors (HIF-PHIs) also known as hypoxia-inducible factor stabilizers (HIF stabilizers) are members of a mostly experimental class of drugs that act by inhibiting hypoxia-inducible factor-proline dioxygenase (HIF prolyl-hydroxylase) which is responsible to break down the hypoxia-inducible factor (HIF) under conditions of normal oxygen concentrations. (en)
rdfs:label
  • HIF prolyl-hydroxylase inhibitor (en)
  • HIF-PH阻害剤 (ja)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License